Bioxytran Statistics
Total Valuation
Bioxytran has a market cap or net worth of 9.78 million. The enterprise value is 11.08 million.
| Market Cap | 9.78M |
| Enterprise Value | 11.08M |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioxytran has 88.99 million shares outstanding. The number of shares has decreased by -16.68% in one year.
| Current Share Class | 88.99M |
| Shares Outstanding | 88.99M |
| Shares Change (YoY) | -16.68% |
| Shares Change (QoQ) | -4.40% |
| Owned by Insiders (%) | 0.56% |
| Owned by Institutions (%) | n/a |
| Float | 88.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -3.61 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.51 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.00
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.54 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -939.80% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 72.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.43% in the last 52 weeks. The beta is 1.84, so Bioxytran's price volatility has been higher than the market average.
| Beta (5Y) | 1.84 |
| 52-Week Price Change | -4.43% |
| 50-Day Moving Average | 0.15 |
| 200-Day Moving Average | 0.11 |
| Relative Strength Index (RSI) | 36.43 |
| Average Volume (20 Days) | 205,526 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.97M |
| Pretax Income | -3.16M |
| Net Income | -3.16M |
| EBITDA | -1.96M |
| EBIT | -1.97M |
| Earnings Per Share (EPS) | -0.03 |
Balance Sheet
The company has 4,348 in cash and 1.26 million in debt, giving a net cash position of -1.26 million or -0.01 per share.
| Cash & Cash Equivalents | 4,348 |
| Total Debt | 1.26M |
| Net Cash | -1.26M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -2.71M |
| Book Value Per Share | -0.03 |
| Working Capital | -2.84M |
Cash Flow
| Operating Cash Flow | -113,493 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bioxytran does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 16.68% |
| Shareholder Yield | n/a |
| Earnings Yield | -32.31% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |